Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Feugier

Showing results (101-110 of 164) with videos related to

Pageof 17
Sort By:
Nature Cancer|April 3, 2025
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA studyGuillaume Cartron, Roch Houot, Yassine Al Tabaa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2022
Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association StudyRené-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2022
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Linmiao Jiang, Jan Walewski, et al.
Haematologica|May 31, 2022
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baselineCédric Rossi, Marc André, Jehan Dupuis, et al.
Blood|September 19, 2022
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysisRoberta Di Blasi, Steven Le Gouill, Emmanuel Bachy, et al.
Haematologica|May 21, 2026
Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapsePierre Sesques, Roch Houot, Yassine Al Tabaa, et al.
Blood|December 22, 2021
Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA studyEmmanuel Bachy, Roch Houot, Pierre Feugier, et al.
Cancers|September 28, 2021
Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 YearsMaxime Jullien, Benoit Tessoulin, Hervé Ghesquières, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2021
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or OlderLucie Oberic, Frederic Peyrade, Mathieu Puyade, et al.
Hemasphere|October 16, 2020
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)Anne Quinquenel, Thérèse Aurran-Schleinitz, Aline Clavert, et al.
Pageof 17

Showing results (101-110 of 164) with videos related to

Sort By:
Pageof 17
Nature Cancer|April 3, 2025
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA studyGuillaume Cartron, Roch Houot, Yassine Al Tabaa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2022
Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association StudyRené-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2022
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Linmiao Jiang, Jan Walewski, et al.
Haematologica|May 31, 2022
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baselineCédric Rossi, Marc André, Jehan Dupuis, et al.
Blood|September 19, 2022
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysisRoberta Di Blasi, Steven Le Gouill, Emmanuel Bachy, et al.
Haematologica|May 21, 2026
Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapsePierre Sesques, Roch Houot, Yassine Al Tabaa, et al.
Blood|December 22, 2021
Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA studyEmmanuel Bachy, Roch Houot, Pierre Feugier, et al.
Cancers|September 28, 2021
Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 YearsMaxime Jullien, Benoit Tessoulin, Hervé Ghesquières, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2021
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or OlderLucie Oberic, Frederic Peyrade, Mathieu Puyade, et al.
Hemasphere|October 16, 2020
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)Anne Quinquenel, Thérèse Aurran-Schleinitz, Aline Clavert, et al.
Pageof 17